(Q34171045)

31 July 2017

1 reference

title

Nontransplant treatment of tyrosinemia (English)

1 reference

31 July 2017

Holme E

1

1 reference

31 July 2017

Lindstedt S

series ordinal

2

1 reference

31 July 2017

publication date

1 November 2000

1 reference

31 July 2017

published in

Clinics in liver disease

1 reference

31 July 2017

volume

4

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

805-814

1 reference

Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Early liver transplantation is indicated for tyrosinemia type I

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

On the enzymic defects in hereditary tyrosinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Surgical and metabolic aspects of liver transplantation for tyrosinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Neurologic crises in hereditary tyrosinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Indications and outcome of liver transplantation in tyrosinaemia type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Liver transplantation in nine Spanish patients with tyrosinaemia type I

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC)

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

NTBC as palliative treatment in chronic tyrosinaemia type I.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

The occurrence of hepatoma in the chronic form of hereditary tyrosinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970142-2

7 January 2021

10.1016/S1089-3261(05)70142-2

Identifiers

DOI

1 reference

release_zd2f2mvpprbb5gka5h46sxpzni

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zd2f2mvpprbb5gka5h46sxpzni

24 November 2022

mapped directly with Wikidata item

1 reference